Olmesartan medoxomil is an angiotensin II (Ang II) receptor blocker (ARB) that has been approved by the US Food and Drug Administration (FDA) for the treatment of hypertension. It is a prodrug that is hydrolysed in the gut into its active metabolite, olmesartan (RNH-6270). Olmesartan is highly selective for the Ang II type 1 receptor (AT1) to which it binds completely and insurmountably and has very little affinity for the other receptor subtypes AT2 and AT4. After oral administration, in animals and humans, it achieves a maximal blood drug concentration within a maximal time of approximately 2 h. It is then slowly eliminated in the urine and faeces. His half-life is approximately 13 h, which makes it suitable for once-daily administration. Olmesartan medoxomil given orally in single daily doses of 20-40 mg has demonstrated significant blood pressure (BP) lowering effects in hypertensive patients. A medline search for the preparation of this manuscript was conducted and revealed 128 references, from 2000 to 2007. Of these, only 16 well-designed prospective clinical trials were selected. The remaining were either animal studies, reviews or studies in progress. In well-designed clinical trials, olmesartan medoxomil has demonstrated similar antihypertensive actions to the other antihypertensive drugs, as well as other members of its class given the highest recommended doses. In addition, the BP lowering effect of olmesartan, like the other members of its class, is greatly enhanced in combination with a diuretic. Its safety profile is similar to the other ARBs and no different than placebo.
Introduction
Olmesartan medoxomil is the 7th latest angiotensin II (Ang II) receptor blocker ARB approved by the Food and Drug Administration (FDA) for the treatment of hypertension. In several randomised placebo-controlled studies, olmesartan medoxomil has demonstrated significant antihypertensive effects compared to placebo. 1, 2 In other comparative studies, olmesartan medoxomil showed similar blood pressure (BP) lowering efficacy with angiotensin converting enzyme (ACE) inhibitors, calcium channel blockers, b-blockers and diuretics, [3] [4] [5] [6] [7] [8] [9] but superior antihypertensive potency against other ARBs given in equivalent starting doses. [10] [11] [12] [13] In other studies, olmesartan medoxomil given in the highest recommended daily doses, its antihypertensive effect was similar to other ARBs. 14 In addition, olmesartan medoxomil, like the other members of its class, has demonstrated an excellent safety profile. 3 
Pharmacokinetic and pharmacodynamic profile
Pharmacokinetic profile Olmesartan medoxomil is a prodrug that is rapidly absorbed and completely hydrolysed in the gastrointestinal tract into its active metabolite olmesartan (RNH6270). The chemical structures of both drugs are depicted in Figure 1 . Olmesartan has 100 000 times greater affinity for the Ang II type 1 receptor AT1 compared to the AT2 receptor, to which it binds competitively and insurmountably. 15, 16 In in vitro studies, the concentration of olmesartan medoxomil required to produce a 50% inhibition of Ang II binding to AT1 receptor (IC 50 ) was 8.070.8 nmol/l, whereas the amount of the drug needed to produce the same IC50 binding of Ang II to the AT2 receptor was greater than 100 000 nmol/l. After oral administration, olmesartan medoxomil given in single doses of 10-160 mg in healthy volunteers, reaches a maximal concentration (C max ) within a maximal time of 1.4-2.8 h. 17, 18 Both the C max and the mean area under the plasma concentration curve (AUC) showed similar linear relationships to the doses given and they were not significantly affected after multiple dose administration. 16 Also, a steady-state of plasma concentration of the drug is usually achieved within 3 days of drug administration in both young and elderly subjects. 17 However, the C max and AUC were 44% higher and the elimination halflife longer (16.5 vs 12.3 h) in the older (475 years) vs the younger (446 years of age) subjects. 17, 19 In addition the C max was affected by renal and liver function, being higher (82 vs 39%) in patients with renal failure vs controls and (48 vs 30%) in patients with moderately severe vs mild liver failure. 19 Olmesartan medoxomil has a 26% bioavailability after oral administration and is mainly eliminated through the gastrointestinal tract and the kidney (50-65 and 10-16%) respectively. 17, 20 The terminal half-life of olmesartan is approximately 13 h, which makes it suitable for once daily administration. The pharmacokinetic profiles of olmesartan medoxomil and the other members of its class are listed in Table 1 .
Pharmacodynamic profile
In vitro studies have shown that the active metabolite of olmesartan medoxomil (RNH 6270) is more potent than the active metabolite of losartan (EXP 3174), since they blocked the Ang II-induced contractions of guinea-pig aorta by 90 and 35%, respectively. 21 Also, the duration of the inhibitory effect of RNH 6270 was longer than that of EXP 3174 (90 vs 60 min, respectively).
In vivo studies in rats, rabbits and monkeys have shown that olmesartan medoxomil possesses antihypertensive, antiproteinuric and antiatherogenic properties, since it blocked the pressor response from the administration of Ang II, reduced the urinary protein excretion of diabetic Zucker rats, and prevented atherosclerotic plaque formation in the aorta of high-cholesterol fed rabbits and cyanomolgus monkeys, compared to controls. 15, [21] [22] [23] In addition, in human volunteers, administration of olmesartan medoxomil 10-40 mg/day blocked the hypertensive response to exogenously administered angiotensin I by greater than 75% for 24 h, compared to controls. 5 
Mechanism of action
Ang II exerts its main haemodynamic and structural effects through stimulation of its AT1 receptor. On the contrary, olmesartan medoxomil, like the other ARBs, interferes with this action of Ang II by selectively blocking the AT1 receptor for which it has a very high affinity and to which it binds selectively and insurmountably. In this respect, the action of the ARBs is indifferent to which pathway the Ang II was generated and they differ from the ACE inhibitors, which only interfere with the generation of Ang II through classical ACE pathway. Recent clinical and experimental studies have shown that up to 40% of Ang II in the blood vessels, heart and kidneys is generated through the alternate pathway via other enzymes and especially Chymase. [24] [25] [26] Olmesartan and the other ARBs in difference to ACE inhibitors, exert a dual haemodynamic effect by selectively blocking the haemodynamic and remodelling actions of Ang II through the AT1 receptor 27 and in addition allowing the Ang II to bind to the unoccupied AT2 receptors. These receptors have effects opposite to those of the AT1 receptors ( Table 2 ). The clinical effects of olmesartan medoxomil in patients with different stages of hypertension have been tested in several multicenter, randomised, double-blind studies, against placebo or active drugs. Most of the studies used patients with a mean sitting diastolic blood pressure (MSDBP) of 4100 o115 mm Hg.
Placebo comparative studies
The studies in this group compared the active drug olmesartan medoxomil in doses ranging from 2.5-80 mg/day against placebo. The duration of most of Treatment of hypertension with olmesartan medoxomil SG Chrysant et al these studies was short (6-12 weeks) with some extended to 52 weeks. Good BP response to treatment was considered a mean sitting diastolic blood pressure (MSDBP) reduction of p90 mm Hg or a decrease in MSDBP X10 mm Hg from baseline. The results of these studies are summarised in Table 3 , and will be briefly discussed here. Pü chler et al., 3 analysed the results of 3055 patients from seven US and European studies. In these studies, olmesartan medoxomil was used in daily doses ranging from 2.5 to 80 mg and resulted in significant, dose dependent reduction of BP up to a dose of 40 mg/day with no further BP reduction with the 80 mg dose. The BP response ranged from 59 to 81% for 2.5 and 40 mg/day dose of olmesartan medoxomil, and 39% for placebo. In a similar study by Brunner and Nussberger, 5 790 patients with a MSDBP X100p115 mm Hg were treated with olmesartan medoxomil 2.5-80 mg/day compared to placebo. Olmesartan medoxomil decreased dosedependently the MSDBP and mean sitting systolic blood pressure (MSSBP) up to 40 mg/day with no further reduction of BP with the 80 mg/day dose. The response of MSDBP to active treatment ranged from 59% for the 2.5 mg/day dose to 77.8% for the 80 mg/day dose, whereas the response to placebo was 45.5%.
In another similar study by Neutel et al., 4 535 patients with MSDBP X100p115 mm Hg were treated with similar daily doses of olmesartan medoxomil given in single doses of 5, 20 and 80 mg or in divided doses of 2.5, 10 and 40 mg, compared to placebo. The BP response to treatment was monitored besides office visits, with ambulatory BP monitoring (ABPM). The BP response to active treatment was dose-dependent and similar with once a day or twice daily administration of the drug, indicating that olmesartan medoxomil is a true once daily drug.
Active comparative studies
Olmesartan medoxomil has been compared for antihypertensive effectiveness with other members of its class as well as other antihypertensive drugs in several multicenter randomised studies, and the results are summarised in Table 3 . In three different studies by Ball et al., 6 olmesartan medoxomil was compared with atenolol, losartan and captopril. Neutel et al.
Brunner et al. In study 1, patients with MSDBP 100-120 mm Hg on hydrochlorothiazide (HCTZ) 25 mg/day, were randomised to olmesartan medoxomil 10 mg/day or atenolol 50 mg/day. The dose of the study drugs could be doubled for better BP control. Of 351 patients 328 were randomised and 318 completed the study. Both drugs decreased the MSDBP/MSSBP to a similar degree, and only 26.2% of olmesartan medoxomil and 28.1% of atenolol received the higher dose.
In study 2, 316 patients with MSDBP 95-114 mm Hg, were randomised to either olmesartan medoxomil 10 mg/day or losartan 50 mg/day, with the doses doubled at 4 weeks if necessary. Of the 316 patients, 271 completed the study. Olmesartan medoxomil produced a greater BP response than losartan and 41.8% of the olmesartan medoxomil vs 63.2% of the losartan group required the doubling of the dose.
In study 3, 291 patients with MSDBP 95-114 mm Hg were randomised to either olmesartan medoxomil 5 mg/day or captopril 12.5 mg twice daily. Of these, 236 completed the study. Olmesartan medoxomil produced a greater reduction in MSDBP/MSSBP than captopril.
In another study by Stumpe et al., 7 381 patients with MSDBP 100-120 mm Hg were randomised to olmesartan medoxomil 20 mg/day, or felodipine 5 mg/day. Both drugs lowered the MSDBP/MSSBP to the same degree.
Chrysant et al. 8 compared the BP lowering effects of olmesartan medoxomil 20 mg/day to amlodipine 5 mg/day in 440 patients with a MSDBP 100-115 mm Hg. The BP was monitored by office visits as well as ABPM. Both drugs had similar BP lowering effects by both office visits as well as mean 24-h ABPM. In a subanalysis of the ABPM results of this study, 28 it was shown that a greater percentage of patients treated with olmesartan medoxomil 20 mg/day achieved the BP goal of o140/90 mm Hg (48%) compared to amlodipine 5 mg/day, (41.9%) and also more patients on olmesartan achieved the more aggressive BP goal of o130/ 85 mm Hg (30.4%) compared with amlodipine (14.0%) or the still more aggressive BP goal of o130/80 mm Hg (18 vs 7.0%) for olmesartan medoxomil and amlodipine, respectively. The antihypertensive effectiveness of olmesartan medoxomil against other members of its class were studied by Oparil et al. 10 in 588 hypertensive patients. In this study, the recommended starting dose of olmesartan medoxomil 20 mg/day was tested against starting doses of losartan 50 mg/day, valsartan 80 mg/day and irbesartan 150 mg/day, by both clinic and ABPM. In this study, the SBP and DBP lowering effects of olmesartan were greater than those of losartan and valsartan (Po0.05) with the exception of SBP which was similar with that of irbesartan ( Figure 2 ). In another similar study, Brunner et al. 13 studied the antihypertensive properties of olmesartan medoxomil against candesartan cilexetil in 645 patients with MSDBP 100-120 mm Hg. In this study, olmesartan medoxomil 20 mg/day was more effective than candesartan cilexetil 8 mg/day (Po0.05) in reducing the MSSBP/MSDBP by clinic as well as by ABPM (Figure 2) . In a recently published study, 14 the escalating doses of olmesartan medoxomil 20-40 mg/day were compared against placebo, losartan 50-100 mg/day and valsartan 80-320 mg/day in 4 weekly intervals for a total of 12 weeks in 696 patients with MSDBP 100-120 mm Hg. In this study the starting dose of olmesartan medoxomil 20 mg/ day had a greater BP lowering effect than the starting doses of losartan 50 mg/day and valsartan 80 mg/day (Po0.05). However, as the doses were escalated to the maximal recommended daily doses, the BP differences between the three treatment regimens disappeared.
Combination treatment
The antihypertensive efficacy of olmesartan medoxomil alone and in combination with HCTZ was studied by Chrysant et al. 9 in a factorial design study in 502 hypertensive patients with MSDBP X100 and p115 mm Hg. In this study, olmesartan medoxomil 10, 20 or 40 mg/day alone and in combination with HCTZ 12.5 and 25.0 mg/day were used. Olmesartan medoxomil in combination with HCTZ produced greater reductions in MSDBP/MSBP than monotherapy with either olmesartan medoxomil or HCTZ. In addition, the response rate to treatment was higher with the drug combination than the individual drugs (Table 4) .
In another study, Sellin et al., 
Treatment indications of ARBs
Olmesartan medoxomil and the other members of its class are recommended as first-line treatment of hypertension, either alone or in combination with other drugs based on the stage of hypertension. 35 In patients with stage-1 hypertension (SBP 140-159 mm Hg or DBP 90-99 mm Hg) treatment can be initiated with the starting doses of olmesartan and if BP is not brought to goal, the dose could be increased to maximum recommended dose of 40 mg/day, and if necessary, drugs from a different class with complimentary action can be added, preferably a diuretic, since such combination can bring the BP to goal in over 70% of the patients. [31] [32] [33] [34] In patients with stage 2 hypertension (SBP X160 mm Hg or DBP X100 mm Hg), treatment can be initiated with a combination therapy. If BP is not brought to goal of o140/90 mm Hg for uncomplicated hypertensives or o130/80 mm Hg for hypertensive patients with diabetes mellitus or renal failure 35 additional drugs with complimentary action should be added. Because of the beneficial effects of ARBs in diabetic patients, the American Diabetes Association has recommended the use of ARBs or ACE inhibitors as firstline therapy in such patients. 36 The angiotensin receptor blockers are truly pleiotropic drugs 37 and have shown effectiveness in reversing left ventricular hypertrophy, 38, 39 in decreasing morbidity and mortality in patients with heart failure [40] [41] [42] [43] [44] and in patients with diabetic nephropathy by decreasing proteinuria and preventing the progression of renal disease. [45] [46] [47] [48] No such studies are available for olmesartan as yet and this drug is not approved by FDA for these conditions (Table 5 ). In addition, ARBs have recently emerged as superior agents for stroke prevention in clinical and experimental studies. 37, [49] [50] [51] [52] [53] [54] [55] In these studies losartan compared to atenolol resulted in a 25 and 40% stroke reduction, in the total study population and in patients with isolated systolic hypertension (ISH) respectively. 39, 51 In other studies, candesartan compared to conventional therapy resulted in 23.4 52 and 40% stroke reduction in the study population and in patients with ISH, respectively. 53, 54 In a Treatment of hypertension with olmesartan medoxomil SG Chrysant et al recent study, eprosartan reduced recurrent strokes by 25% compared to nitrendipine for a similar BP control, in hypertensive patients with a previous stroke. Similar results were also reported from a recent Japanese study, in which high-risk patients treated with a valsartan-based regimen had a 40% lower stroke incidence than patients treated with other drugs for the same BP reduction. 55 The results of the VALUE study, 56 where valsartan was compared to amlodipine 55 were disappointing initially due to poor BP control with valsartan. However, as the study progressed and the BP differences between the two treatment groups were narrowed, the stroke incidence decreased in the valsartan treated group even though the BP was 1.8/1.5 mm Hg higher compared to amlodipine treated group. Despite this, the overall stroke incidence was higher by 15% in the valsartan treated group accounting for the higher incidence of early strokes. This study clearly demonstrated the critical role of early and sustained BP control in stroke prevention. The conditions for which the ARBs have shown benefit and their use is recommended by the JNC-7, 35 except for stroke, are listed in Table 5 . Other beneficial effects of some of the ARBs include their; (a) antiatherogenic, 57, 58 (b) antioxidant, 59 (c) antidiabetic, 60 (d) antiplatelet 61 and (e) atrial antifibrillatory effects. 62, 63 All these effects of ARBs could contribute to their stroke protective effects independent of BP control. No such data are available for olmesartan medoxomil as yet.
Safety profile of olmesartan medoxomil
Olmesartan medoxomil is a safe and well-tolerated drug, like the other members of its class. The incidence of adverse events reported by the patients from the various clinical trials was similar between the olmesartan medoxomil (51.5%) and the placebotreated ones (47.2%). The most commonly reported drug emergent side effects were headache, dizziness, flu-like symptoms and bronchitis, which were no different from the placebo treated patients. Also, the metabolic profile of olmesartan medoxomil was excellent and no different from placebo. In recent database reviews of more than 56 000 patients followed for 1-4.5 years, ARBs were better tolerated and much less discontinued than ACE inhibitors, calcium channel blockers, diuretics or b-blockers.
64,65
Future studies
There are several large clinical outcome studies with ARBs in progress, which when completed will provide useful clinical information. The Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET), is evaluating the effects of telmisartan 80 mg/day, ramipril 10 mg/day and their combination in a parallel group design study on cardiovascular and cerebrovascular morbidity and mortality, and new onset diabetes mellitus in 23 400 high risk patients. 66 A sister study, the Telmisartan Randomised Assessment Study in ACEI intolerant patients with Cardiovascular Disease (TRANSCEND) is testing telmisartan 80 mg/day vs placebo in the ONTARGET population who are intolerant to ACEIs. 66 An important study, which will be complementary to these studies is the Prevention Regimen For Effectively avoiding Second Strokes (PRoFESS), in which 15 500 patients with a previous stroke are being treated with either telmisartan 80 mg/day or extended release dipyridamole 200 mg þ clopidogrel 75 mg/day. 67 This study will be completed in 2007. Another very important study is the Randomised Olmesartan And Diabetes Microalbuminuria Prevention Study (ROADMAP), which is evaluating the antiproteinuric and renal protective effects of olmesartan medoxomil 40 mg/ day in type II diabetic patients without proteinuria at study enrollment. 68 This study will enroll 4400 such patients and monitor them for 5 years. The results of the ONTARGFET and TRANSCEND studies are expected to be reported in 2007, whereas those of the ROADMAP in 2015.
Discussion
It is now well established that the renin-angiotensin-aldosterone system plays an important role in cardiovascular homeostasis. Its effector hormone, Ang II exerts its haemodynamic and cardiovascular remodelling effects through stimulation of the AT1 receptors. Drugs that interfere with its actions by blocking its binding to the AT1 receptors (ARBs) offer the greatest protection against the deleterious effects of Ang II. Several small, as well as large clinical outcome studies have demonstrated 69, 70 In addition, the ongoing large clinical outcomes study (ROADMAP), will provide useful information regarding its renoprotective and antiproteinuric effects in type II diabetic patients when completed. 68 However, despite the putative cardioprotective, renoprotective and stroke protective effects of ARBs beyond BP control, the major protection is conferred through good BP control. According to the JNC-7 guidelines 35 aggressive BP control of o140/90 mm Hg for patients with uncomplicated hypertension, or o130/80 mm Hg for hypertensive patients with type II diabetes mellitus or renal disease is necessary to prevent BP related complications. Since monotherapy only controls 50% of mild to moderate hypertensive patients, drug combination therapy is often required to achieve BP goals, and patients with a sitting office BP of X160/ 100 mm Hg, should be started with double therapy initially. The most effective combination therapy from the studies presented in this review, is an ARB with a low-dose diuretic. If this therapy is not effective, other drugs from a different class with complimentary action, such as a calcium channel blocker or a b-blocker, should be added to achieve BP goal. In several cases, four or even five different antihypertensive drugs are needed to bring BP to goal. Disclosures No financial or editorial support was provided for the preparation of this manuscript. There are no conflicts of interest.
